Tuberculosis (TB) is an ancient scourge caused by Mycobacterium tuberculosis which may have originated about 20,000 – 15,000 years ago1. Of the estimated 9 million people who developed TB in 2013, more than half (56%) were in the South-East Asia and Western Pacific Regions. India alone accounted for 24% of global stages2. The trial was conducted to establish the efficacy of the ‘VardhamānaPippalīRasāyana’ as an adjuvant therapy in the management of newly diagnosed cases of the Pulmonary Tuberculosis. The patients recruited were divided in two groups Group1 received DOTS regimen As recommended in RNTCP program (2 HREZ+4 HR) in supervision of DOTS (worker on alternate days of week).Group 2 received DOTS regimen As recommended in RNTCP program (2 HREZ/4 HR) in supervision of DOTS worker on alternate days of week along with ‘Vardhamāna Pippalī Rasāyana’ . The patients who received DOTS treatment along with ‘Vardhamāna Pippalī Rasāyana’ exhibited significant improvement in AFB reversibility, Weight gain, Hemoglobin ( Hb%) and normalization of ESR. So DOTS treatment along with ‘Vardhamāna Pippalī Rasāyana’ is a promising treatment strategy for management of Pulmonary tubesrculosis.
Keywords: Vardhmāna PippaliRasayana, DOTS, TB